Phase III trial of tislelizumab + pemetrexed for first-line NSCLC met the primary endpoint of progression-free survival at interim analysis,- BeiGene
Related news and insights
BeiGene, Ltd. announced that the first patient was dosed in the global Phase III AdvanTIG-302 trial of BeiGene’s investigational anti-TIGIT antibody ociperlimab (BGB A1217) in combination with its anti-PD-1 antibody tislelizumab , for the first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) as monotherapy in two advanced cancers.
Genentech, a member of the Roche Group announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50-0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumors express PD-L1?1%, compared with best supportive care (BSC).